{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:19:19Z","timestamp":1761718759634,"version":"3.44.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T00:00:00Z","timestamp":1545264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["81625016","17YF1402500"],"award-info":[{"award-number":["81625016","17YF1402500"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1053\/j.seminoncol.2018.12.004","type":"journal-article","created":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T17:20:10Z","timestamp":1545931210000},"page":"39-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Selecting chemotherapy for pancreatic cancer: Far away or so close?"],"prefix":"10.1053","volume":"46","author":[{"given":"Si","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianjun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2018.12.004_bib0001","first-page":"7","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0002","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","article-title":"Pancreatic cancer","volume":"388","author":"Kamisawa","year":"2016","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0003","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1002\/cncr.26553","article-title":"Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent","volume":"118","author":"Mayo","year":"2012","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000267","article-title":"Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages","volume":"7","author":"Gillen","year":"2010","journal-title":"PLoS Med"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0005","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1200\/JOP.2016.015818","article-title":"Evolution of the management of resectable pancreatic cancer","volume":"12","author":"Tsai","year":"2016","journal-title":"J Oncol Pract"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0006","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.suc.2016.07.004","article-title":"Adjuvant and neoadjuvant therapy for resectable pancreatic and periampullary cancer","volume":"96","author":"Kim","year":"2016","journal-title":"Surg Clin North Am"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0007","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrc3237","article-title":"Combining immunotherapy and targeted therapies in cancer treatment","volume":"12","author":"Vanneman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0008","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrclinonc.2015.53","article-title":"Pancreatic cancer: from state-of-the-art treatments to promising novel therapies","volume":"12","author":"Garrido-Laguna","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0009","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ejso.2006.10.004","article-title":"Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer","volume":"33","author":"Goonetilleke","year":"2007","journal-title":"Eur J Surg Oncol"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0010","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.7150\/jca.18901","article-title":"Diagnostic accuracy of a CA125-based biomarker panel in patients with pancreatic cancer: a systematic review and meta-analysis","volume":"8","author":"Meng","year":"2017","journal-title":"J Cancer"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0011","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.2147\/OTT.S145708","article-title":"Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis","volume":"10","author":"Meng","year":"2017","journal-title":"Onco Targets Ther"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0012","first-page":"835","article-title":"CA 19-9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy","volume":"23","author":"Micke","year":"2003","journal-title":"Anticancer Res"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0013","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00280-013-2313-8","article-title":"A retrospective analysis of early CA199 change in salvage chemotherapy for refractory pancreatic cancer","volume":"72","author":"Nakai","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0014","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.6004\/jnccn.2017.0131","article-title":"Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Tempero","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0015","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1245\/s10434-017-6076-z","article-title":"Redefining the positive margin in pancreatic cancer: impact on patterns of failure, long-term survival and adjuvant therapy","volume":"24","author":"Osipov","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0016","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1097\/SLA.0000000000002345","article-title":"R0 Versus R1 resection matters after pancreaticoduodenectomy, and less after distal or total pancreatectomy for pancreatic cancer","volume":"268","author":"Demir","year":"2017","journal-title":"Ann Surg"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0017","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/SLA.0000000000002432","article-title":"Prognostic value of resection margin involvement after pancreaticoduodenectomy for ductal adenocarcinoma: updates from a french prospective multicenter study","volume":"266","author":"Delpero","year":"2017","journal-title":"Ann Surg"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0018","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1200\/JCO.2016.67.5553","article-title":"Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline","volume":"34","author":"Khorana","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0019","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0020","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0021","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2016.67.5561","article-title":"Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline","volume":"34","author":"Balaban","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0022","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2016.67.1412","article-title":"Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline","volume":"34","author":"Sohal","year":"2016","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"10.1053\/j.seminoncol.2018.12.004_bib0023","doi-asserted-by":"crossref","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","article-title":"Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Ducreux","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0024","doi-asserted-by":"crossref","DOI":"10.1159\/000477850","article-title":"Retrospective analysis of CA19-9 decrease in patients with metastatic pancreatic carcinoma treated with FOLFIRINOX or gemcitabine in a randomized phase III study (ACCORD11\/PRODIGE4)","volume":"93","author":"Robert","year":"2017","journal-title":"Oncology"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0025","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/annonc\/mdw006","article-title":"CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer","volume":"27","author":"Chiorean","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0026","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","article-title":"Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial","volume":"29","author":"Von Hoff","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0027","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0028","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S0140-6736(01)06651-X","article-title":"Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial","volume":"358","author":"Neoptolemos","year":"2001","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0029","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/00000658-200112000-00007","article-title":"Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and\/or chemotherapy in the ESPAC-1 randomized controlled trial","volume":"234","author":"Neoptolemos","year":"2001","journal-title":"Ann Surg"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0030","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial","volume":"310","author":"Oettle","year":"2013","journal-title":"JAMA"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0031","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0032","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2012.7352","article-title":"Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial","volume":"308","author":"Neoptolemos","year":"2012","journal-title":"JAMA"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0033","doi-asserted-by":"crossref","first-page":"djt347","DOI":"10.1093\/jnci\/djt347","article-title":"Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial","volume":"106","author":"Greenhalf","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0034","article-title":"Imaging biomarkers of tumor response in neuroendocrine liver metastases treated with transarterial chemoembolization: can enhancing tumor burden of the whole liver help predict patient survival?","author":"Sahu","year":"2016","journal-title":"Radiology"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0035","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.canlet.2015.01.023","article-title":"Metabolic tumor burden: a new promising way to reach precise personalized therapy in PDAC","volume":"359","author":"Xiang","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0036","doi-asserted-by":"crossref","first-page":"37923","DOI":"10.18632\/oncotarget.13544","article-title":"Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment","volume":"8","author":"Rao","year":"2015","journal-title":"Oncotarget"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0037","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10456-016-9503-z","article-title":"The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth","volume":"19","author":"Yapp","year":"2016","journal-title":"Angiogenesis"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0038","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1053\/j.gastro.2012.06.006","article-title":"Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma","volume":"143","author":"Marechal","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0039","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/SLA.0000000000001837","article-title":"Does size matter in pancreatic cancer?","volume":"266","author":"Marchegiani","year":"2017","journal-title":"Ann Surg"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0040","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/SLA.0000000000001763","article-title":"Multi-institutional validation study of the American Joint Commission on Cancer (8th Edition) changes for T and N staging in patients with pancreatic adenocarcinoma","volume":"265","author":"Allen","year":"2017","journal-title":"Ann Surg"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0041","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.canlet.2015.02.014","article-title":"Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer","volume":"360","author":"Shi","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0042","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.ultrasmedbio.2016.12.009","article-title":"2-D and 3-D ultrasound for tumor volume analysis: a prospective study","volume":"43","author":"Gonz\u00e1lez","year":"2017","journal-title":"Ultrasound Med Biol"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0043","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/MPA.0000000000000035","article-title":"Three-dimensional reconstruction of the peripancreatic vascular system based on computed tomographic angiography images and its clinical application in the surgical management of pancreatic tumors","volume":"43","author":"Fang","year":"2014","journal-title":"Pancreas"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0044","first-page":"1","article-title":"Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy","author":"Mellon","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0045","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1245\/s10434-014-3842-z","article-title":"Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma","volume":"21","author":"Boone","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0046","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jconrel.2013.05.041","article-title":"nab-Paclitaxel mechanisms of action and delivery","volume":"170","author":"Yardley","year":"2013","journal-title":"J Control Release"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0047","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000358890","article-title":"Nab-paclitaxel for metastatic pancreatic cancer: clinical outcomes and potential mechanisms of action","volume":"37","author":"Al-Batran","year":"2014","journal-title":"Oncol Res Treat"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0048","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1158\/1078-0432.CCR-07-4592","article-title":"Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel","volume":"14","author":"Gardner","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0049","first-page":"337","article-title":"Neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel reduces the number of cancer-associated fibroblasts through depletion of pancreatic stroma","volume":"38","author":"Miyashita","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0050","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/bjc.2016.215","article-title":"Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer","volume":"115","author":"Rajeshkumar","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0051","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/bjc.2013.415","article-title":"Stromal disrupting effects of nab-paclitaxel in pancreatic cancer","volume":"109","author":"Alvarez","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0052","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00018-017-2678-7","article-title":"Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?","volume":"75","author":"Liang","year":"2018","journal-title":"Cell Mol Life Sci"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0053","first-page":"128","article-title":"High serum levels of DUPAN2 antigen and CA19-9 in pancreatic cancer: correlation with immunocytochemical localization of antigens in cancer cells","volume":"35","author":"Suzuki","year":"1988","journal-title":"Hepatogastroenterology"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0054","doi-asserted-by":"crossref","first-page":"6424","DOI":"10.3748\/wjg.v22.i28.6424","article-title":"Re-evaluation of classical prognostic factors in resectable ductal adenocarcinoma of the pancreas","volume":"22","author":"Akerberg","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0055","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/jamasurg.2015.0668","article-title":"Characteristics of 10-year survivors of pancreatic ductal adenocarcinoma","volume":"150","author":"Paniccia","year":"2015","journal-title":"JAMA Surg"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0056","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.pan.2015.09.008","article-title":"Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: a multi-center retrospective study","volume":"15","author":"Matsumoto","year":"2015","journal-title":"Pancreatology"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0057","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1245\/s10434-012-2809-1","article-title":"CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy","volume":"20","author":"Hartwig","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0058","doi-asserted-by":"crossref","first-page":"824","DOI":"10.4143\/crt.2016.336","article-title":"Impact of Resection Margin Distance on Survival of Pancreatic Cancer: A Systematic Review and Meta-Analysis","volume":"49","author":"Kim","year":"2017","journal-title":"Cancer Res Treat"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0059","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/SLA.0000000000001731","article-title":"Pancreatic cancer surgery: the new R-status counts","volume":"265","author":"Strobel","year":"2017","journal-title":"Ann Surg"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0060","first-page":"437","article-title":"Targeted therapies: Notching up dormant tumour-cell deaths to avoid recurrence","volume":"12","author":"Hutchinson","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0061","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/bs.acr.2016.07.002","article-title":"The relationship between dormant cancer cells and their microenvironment","volume":"132","author":"Linde","year":"2016","journal-title":"Adv Cancer Res"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0062","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3390\/vaccines3030597","article-title":"Cancer dormancy: a regulatory role for endogenous immunity in establishing and maintaining the tumor dormant state","volume":"3","author":"Baxevanis","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0063","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.molonc.2016.09.009","article-title":"Tumor cell dormancy","volume":"11","author":"Gomis","year":"2017","journal-title":"Mol Oncol"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0064","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10637-014-0157-7","volume":"33","author":"Beane","year":"2015","journal-title":"Invest New Drugs"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0065","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1200\/EDBK_159117","article-title":"The past, present, and future of pancreatic cancer clinical trials","volume":"35","author":"Matrisian","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0066","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.soc.2015.11.010","article-title":"Adjuvant and neoadjuvant therapy for pancreatic cancer","volume":"25","author":"Li","year":"2016","journal-title":"Surg Oncol Clin N Am"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0067","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1200\/JCO.2016.68.5081","article-title":"Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis","volume":"35","author":"Mokdad","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0068","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183288","article-title":"Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: results from the PRODIGE 4\/ ACCORD 11 randomized trial","volume":"12","author":"Lambert","year":"2017","journal-title":"PLoS One"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0069","doi-asserted-by":"crossref","first-page":"731","DOI":"10.21873\/invivo.11122","article-title":"Locally advanced or metastatic pancreatic adenocarcinoma: easily available factors of predictive prolonged survival under gemcitabine","volume":"31","author":"Ploquin","year":"2017","journal-title":"In Vivo"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0070","doi-asserted-by":"crossref","first-page":"29925","DOI":"10.18632\/oncotarget.15557","article-title":"A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancer","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0071","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2217\/fon.16.16","article-title":"Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature","volume":"12","author":"Caparello","year":"2016","journal-title":"Future Oncol"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0072","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s00432-015-1953-y","article-title":"A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy","volume":"141","author":"Xue","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0073","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00432-012-1371-3","article-title":"Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy","volume":"139","author":"Haas","year":"2013","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0074","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/jgh.13075","article-title":"Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer","volume":"31","author":"Chung","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0075","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/cncr.27734","article-title":"Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials","volume":"119","author":"Bauer","year":"2013","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0076","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2147\/OTT.S116136","article-title":"Combination of preoperative CEA and CA19-9 improves prediction outcomes in patients with resectable pancreatic adenocarcinoma: results from a large follow-up cohort","volume":"10","author":"Zhou","year":"2017","journal-title":"Onco Targets Ther"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0077","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/SLA.0000000000001837","article-title":"Does size matter in pancreatic cancer?: reappraisal of tumour dimension as a predictor of outcome beyond the TNM","volume":"266","author":"Marchegiani","year":"2017","journal-title":"Ann Surg"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0078","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jamcollsurg.2016.02.009","article-title":"Carbohydrate antigen 19-9 elevation in anatomically resectable, early stage pancreatic cancer is independently associated with decreased overall survival and an indication for neoadjuvant therapy: a national cancer database study","volume":"223","author":"Bergquist","year":"2016","journal-title":"J Am Coll Surg"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0079","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.surg.2013.10.024","article-title":"A new preoperative prognostic scoring system to predict prognosis in patients with locally advanced pancreatic body cancer who undergo distal pancreatectomy with en bloc celiac axis resection: a retrospective cohort study","volume":"155","author":"Miura","year":"2014","journal-title":"Surgery"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0080","doi-asserted-by":"crossref","first-page":"5918","DOI":"10.1200\/JCO.2008.18.6288","article-title":"Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704","volume":"26","author":"Berger","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0081","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.pan.2016.04.007","article-title":"Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: a retrospective cohort study","volume":"16","author":"Imaoka","year":"2016","journal-title":"Pancreatology"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0082","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/hpb.12154","article-title":"Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer","volume":"16","author":"Tzeng","year":"2014","journal-title":"HPB (Oxford)"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0083","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijrobp.2012.11.020","volume":"86","author":"Vainshtein","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0084","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1186\/1471-2407-12-609","article-title":"Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis","volume":"12","author":"Mayahara","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0085","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1136\/jclinpath-2014-202451","article-title":"Combination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancer","volume":"68","author":"Reitz","year":"2015","journal-title":"J Clin Pathol"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0086","doi-asserted-by":"crossref","first-page":"e78977","DOI":"10.1371\/journal.pone.0078977","article-title":"Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1,446 patients from the pancreatic cancer cohort in a single institution","volume":"8","author":"Park","year":"2013","journal-title":"PLoS One"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0087","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejso.2014.09.006","article-title":"High serum CA 19-9 but not tumor size should select patients for staging laparoscopy in radiological resectable pancreas head and peri-ampullary cancer","volume":"41","author":"Alexakis","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0088","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1111\/j.1440-1746.2009.05935.x","article-title":"Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?","volume":"24","author":"Kim","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0089","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1245\/s10434-008-0134-5","article-title":"Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma","volume":"15","author":"Maithel","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0090","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.3748\/wjg.14.3750","article-title":"Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma","volume":"14","author":"Zhang","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0091","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00534-006-1184-3","article-title":"Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma","volume":"14","author":"Fujioka","year":"2007","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0092","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1200\/JCO.2005.05.3934","article-title":"Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma","volume":"24","author":"Ferrone","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.12.004_bib0093","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.gassur.2005.06.008","article-title":"CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer","volume":"9","author":"Karachristos","year":"2005","journal-title":"J Gastrointest Surg"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775417301380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775417301380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:55:23Z","timestamp":1758804923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775417301380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0093775417301380"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2018.12.004","relation":{},"ISSN":["0093-7754"],"issn-type":[{"type":"print","value":"0093-7754"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selecting chemotherapy for pancreatic cancer: Far away or so close?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2018.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}